Background-Pulmonary arterial hypertension (PAH) is characterized, in part, by decreased endothelial nitric oxide (NO · ) production and elevated levels of endothelin-1. Endothelin-1 is known to stimulate endothelial nitric oxide synthase (eNOS) via the endothelin-B receptor (ET B ), suggesting that this signaling pathway is perturbed in PAH. Endothelin-1 also stimulates adrenal aldosterone synthesis; in systemic blood vessels, hyperaldosteronism induces vascular dysfunction by increasing endothelial reactive oxygen species generation and decreasing NO · levels. We hypothesized that aldosterone modulates PAH by disrupting ET B -eNOS signaling through a mechanism involving increased pulmonary endothelial oxidant stress. Methods and Results-In rats with PAH, elevated endothelin-1 levels were associated with elevated aldosterone levels in plasma and lung tissue and decreased lung NO · metabolites in the absence of left-sided heart failure. In human pulmonary artery endothelial cells, endothelin-1 increased aldosterone levels via peroxisome proliferator-activated receptor gamma coactivator-1␣/steroidogenesis factor-1-dependent upregulation of aldosterone synthase. Aldosterone also increased reactive oxygen species production, which oxidatively modified cysteinyl thiols in the eNOS-activating region of ET B to decrease endothelin-1-stimulated eNOS activity. Substitution of ET B -Cys405 with alanine improved ET B -dependent NO · synthesis under conditions of oxidant stress, confirming that Cys405 is a redox-sensitive thiol that is necessary for ET B -eNOS signaling. In human pulmonary artery endothelial cells, mineralocorticoid receptor antagonism with spironolactone decreased aldosterone-mediated reactive oxygen species generation and restored ET B -dependent NO · production. Spironolactone or eplerenone prevented or reversed pulmonary vascular remodeling and improved cardiopulmonary hemodynamics in 2 animal models of PAH in vivo. Conclusions-Our findings demonstrate that aldosterone modulates an ET B cysteinyl thiol redox switch to decrease pulmonary endothelium-derived NO · and promote PAH. (Circulation. 2012;126:963-974.)
P ulmonary endothelial reactive oxygen species (ROS) have been implicated in the pathobiology of pulmonary arterial hypertension (PAH) and have been shown to disrupt nitric oxide (NO · )-dependent vasodilatory signaling pathways to promote pulmonary vasoconstriction, muscularization of pulmonary arterioles, and perivascular fibrosis. 1, 2 However, contemporary PAH pharmacotherapies that aim to restore pulmonary vascular NO · levels have waning long-term efficacy and do not maintain normal pulmonary vascular tone and pulmonary hemodynamics. 3 This observation suggests that, in PAH, perturbations to the redox milieu of pulmonary vascular tissue is sufficient to offset the vasodilatory effects of NO · , although the factor(s) that modulate this effect have not been fully elucidated.
Clinical Perspective on p 974
Elevated levels of the mineralocorticoid hormone aldosterone are associated with a vasculopathy in systemic blood vessels that is characterized by mineralocorticoid receptordependent increases in endothelial ROS generation that de-creases levels of bioavailable NO · resulting in vascular endothelial dysfunction, vascular fibrosis, and decreased vascular compliance. 4 In patients with hyperaldosteronism and hypertension or congestive heart failure, mineralocorticoid receptor antagonism with spironolactone or eplerenone improves vascular reactivity and attenuates the adverse effects of aldosterone on blood vessel function and architecture. 5 We hypothesized that hyperaldosteronism is present in PAH owing to increased circulating levels of endothelin-1 (ET-1), which is a potent stimulus of adrenal aldosterone synthesis, 6 and/or overactivation of the renin-angiotensin-aldosterone axis. Together, these observations and the derivative hypothesis suggest the possibility that by increasing pulmonary endothelial ROS levels, hyperaldosteronism is an unrecognized contributor to the pathobiology of PAH.
The mechanism(s) by which ROS decreases pulmonary endothelial NO · levels in PAH is unresolved. In the systemic vasculature, ROS has been implicated in the oxidative modification of redox-sensitive cysteinyl thiols in regulatory proteins involved in NO · -dependent vasodilatory signaling to decrease NO · bioactivity. 7 A key source of endogenous NO · generation in pulmonary endothelial cells is via endothelin type B receptor (ET B )-mediated activation of endothelial nitric oxide synthase (eNOS). 8 ET B contains an intracellular cysteine-rich region near its carboxyterminal domain that includes Cys405, demonstrated previously to be a cysteinyl thiol that regulates ET B signal transduction. 9 Taken together, we hypothesized that oxidative modification of ET B Cys405 by aldosterone-induced ROS serves as a redox switch that disables ET B -dependent synthesis of NO · to promote pulmonary vascular dysfunction and negative remodeling of pulmonary arterioles in PAH.
Methods
An expanded Methods section is located in the online-only Data Supplement.
Cell Culture and Treatments
Human pulmonary artery endothelial cells (HPAECs) (Lonza) (male donors) were grown to confluence by using phenol-free EGM-2 medium supplemented with 5% fetal bovine serum at 37°C, 5% CO 2 . Cells were passaged twice weekly by using 0.5% trypsin/EDTA, and experiments were performed on cells from passages 4 to 10. Aldosterone (Steraloids) and ET-1 (1-100 nmol/L) (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (10 nmol/L) and deoxygenated water, respectively, which served as vehicle controls. Cells were treated with aldosterone (10 Ϫ9 -10 Ϫ7 mol/L) for 24 hours and, in selected experiments, coincubated with the mineralocorticoid receptor inhibitor spironolactone (10 mol/L) (Sigma-Aldrich).
Western Analysis to Detect ET B Disulfide Bond Formation
Western analysis to detect ET B disulfide bond formation was performed as described previously. 7 In brief, protein extracts from cells were lysed in alkylating buffer containing 0.1 mol/L Tris-HCl, pH 6.8, 1% SDS, 100 mmol/L iodoacetamide, and 100 mmol/L N-ethylmaleimide, and sonicated on ice for 5 minutes followed by a 30-minute incubation at 25°C. Alkylated proteins were then precipitated with acetone. Proteins were resuspended in 50 L of 0.1 mol/L Tris-HCl, pH 7.4, 1% SDS; and disulfides were reduced with 5 mmol/L tris(2-carboxyethyl)phosphine hydrochloride. After a 20-minute incubation at 25°C, tris(2-carboxyethyl)phosphine hydrochloride was removed with a Micro Bio-Spin column 6 (Bio-Rad), and 1% SDS was added to the eluent. The cysteines previously participating in a disulfide bond, now reduced, were labeled with 1 mmol/L polyethylene glycol-conjugated maleimide (molecular mass 10 kDa) (Fluka). After a 1-hour incubation at 25°C, proteins were precipitated with acetone, resuspended in 50 L of nonreducing SDS electrophoresis buffer, and boiled for 10 minutes. Protein samples were then size-fractionated electrophoretically by using SDS-PAGE, and transferred to a polyvinylidene fluoride membrane. The membrane was immunoblotted with an anti-ET B antibody to the region of ET B that contains Cys405 (amino acid sequence to which ET B antibody was raised: CLCCWCQSFEEKQSLEEKQSCLKF-KANDHGYDNFRSSNKYSSS) (Santa Cruz Biotechnology). Bands were visualized by using the enhanced chemiluminescence detection method. 4
Animal Models of PAH
Male Sprague-Dawley rats (age 12-14 weeks; Charles River Laboratories) were handled in accordance with US National Institutes of Health guidelines, and all procedures were approved by the local committee at Brigham and Women's Hospital, Harvard Medical School. All surgeries were performed under ketamine/xylazine anesthesia. For the monocrotaline (MCT) model of PAH, rats were fed standard chow and treated with a 0.5-mL intraperitoneal injection of MCT (50 mg/mL) (Sigma-Aldrich) or 0.9% saline as control. Rats were randomly assigned to spironolactone (25 mg/kg per day) (Henry Schein) or vehicle added to the drinking water. For the prevention study, treatment with spironolactone began immediately following administration of MCT and continued for 23 to 25 days until hemodynamic and tissue analyses were performed. For the reversal study, a second experiment was performed in which rats were randomly assigned to spironolactone or vehicle that was initiated 14 days following the administration of MCT and continued until hemodynamic and tissue analyses were performed 10 days later.
For SU-5416/hypoxia-induced PAH, rats (Ϸ225 g) were administered a single subcutaneous injection of the vascular endothelial growth factor-2 inhibitor SU-5416 (20 mg/kg; Sigma) and exposed immediately to chronic hypoxia (barometric pressure, 410 mm Hg; inspired O 2 tension 76 mm Hg) as described previously. 10 Rats were randomly assigned to either the selective mineralocorticoid receptor antagonist eplerenone (0.6 mg/1 g standard chow; Test Diet Inc) or standard chow as a control. 11 Hemodynamic and tissue analyses were performed on all rats 21 days following exposure to chronic hypoxia.
(RV) free-wall thickness (0.58Ϯ0.05 versus 1.1Ϯ0.05 mm, PϽ0.03, nϭ6). Right heart catheterization confirmed that MCT increased significantly pulmonary artery systolic pressure (PASP) (assumed to be equivalent to RV systolic pressure in the setting of a normal pulmonic valve) ( 1-197.4 ] pg/g protein, PϽ0.04, nϭ4) in plasma and lung tissue, respectively ( Figure  1C and 1D).
The finding of increased aldosterone levels in lung tissue suggested that PAH may be associated with extra-adrenal aldosterone synthesis. To determine whether this occurred, we examined lungs for expression of the enzyme CYP11B2 (aldosterone synthase), which catalyzes the final and ratelimiting step in aldosterone steroidogenesis. Following saline perfusion of lungs before organ harvest, protein levels of CYP11B2 were increased significantly in lung tissue of rats with PAH in comparison with controls (483Ϯ75 versus 1319Ϯ226 arbitrary units, PϽ0.03, nϭ4) (online-only Data Supplement Figure I ), indicating that it is plausible that elevated levels of aldosterone in lung tissue may also result from local synthesis of aldosterone in PAH.
Aldosterone Increases Pulmonary Artery Pressure and Pulmonary Vascular Remodeling in PAH in Vivo
To determine whether hyperaldosteronism contributes to increased pulmonary artery pressure in PAH in vivo and mineralocorticoid receptor antagonism could prevent PAH, rats were treated with spironolactone (25 mg/kg per day) or V starting at the time of MCT injection. We observed that, without significantly decreasing plasma ET-1 levels or influencing body weight, mean arterial pressure or left ventricular end-diastolic pressure (online-only Data Supplement Figure  II) , spironolactone decreased PASP significantly in PAH (89.3Ϯ5.2 versus 69.5Ϯ5.4 mm Hg, PϽ0.01, nϭ6) ( Figure  2A ), which was confirmed by an increase in pulmonary artery flow acceleration time (14.1Ϯ1.2 versus 22.3Ϯ2.2 ms, PϽ0.005, nϭ6) ( Figure 2B ). Spironolactone also decreased RV free-wall thickness (1.07Ϯ0.05 versus 0.86Ϯ0.03 mm, PϽ0.03, nϭ6) ( Figure 2C ) and RV weight (0.43Ϯ0.07 versus 0.35Ϯ0.04 RV weight/LV septum weight, Pϭ0.22, nϭ5) (online-only Data Supplement Figure III) . Notably, these findings were associated with increased levels of the stable NO · metabolite, nitrite (NO 2 Ϫ ), in lung tissue specimens harvested from spironolactone-treated rats with PAH in comparison with V-treated rats with PAH (759Ϯ55 versus 506Ϯ86 mol/L/g protein, Pϭ0.048, nϭ4), indicating that spironolactone improved NO · bioavailability ( Figure 3A ). Spironolactone also prevented pathophenotypic changes to distal pulmonary arterioles (located distal to terminal bronchioles with diameters 20 -50 m 13 ) as demonstrated by immunohistochemical staining for smooth muscle ␣-actin. In comparison with V-treated rats with PAH, spironolactone decreased the number of ␣-actin-stained muscularized distal pulmonary arterioles (76.0 [64 -95] versus 59.5 [59 -61] muscularized pulmonary arterioles per 20 high-powered fields, PϽ0.005, nϭ5) ( Figure 3B ), and increased significantly the cross-sectional luminal area of vessels (13.7 [12.7-16.1] versus 36.8 [30.1-38 .0] % cross-sectional area, PϽ0.02, nϭ5). Furthermore, Gomori's trichrome staining of rat lung sections revealed that, in comparison with V-treated rats with PAH, spironolactone decreased perivascular collagen deposition by 77% (PϽ0.001, nϭ4 -5 rats per condition), similar to levels observed in rats without PAH ( Figure 3C ). Analysis using picrosirius red staining paralleled these findings, indicating that hyperaldosteronism contributed to perivascular collagen deposition (ie, fibrillar collagen), which, in turn, is strongly associated with impaired vascular compliance in PAH (online-only Data Supplement Figure IV ). 1 To determine whether aldosterone antagonism reverses established PAH, a second study was performed in which V or spironolactone (25 mg/kg per day) was initiated 14 days following administration of MCT, a time point associated with histological evidence of MCT-induced inflammatory injury to distal pulmonary arterioles (online-only Data Supplement Figure V ). In comparison with V-treated rats with PAH, spironolactone decreased levels of perivascular collagen by 71% (Pϭ0.03, nϭ6), which was associated with a significant decrease in indexed pulmonary vascular resistance (35.9Ϯ3.2 versus 21.5Ϯ3.2 mm Hgϫminϫg/mL, nϭ4, PϽ0.02) and PASP (60.3Ϯ5.2 versus 39.5Ϯ4.1 mm Hg, nϭ6, PϽ0.005) without changes to heart rate, cardiac index, left ventricular end-diastolic pressure, mean arterial pressure, or indexed systemic vascular resistance ( Figure 4A ).
Next, to confirm the role of aldosterone in a second animal model of PAH and to determine whether there was a class effect for mineralocorticoid receptor antagonists, we studied the preventive effects of eplerenone on the development of abnormal cardiopulmonary hemodynamics in rats administered SU-5416 and exposed to chronic hypoxia for 21 days. In comparison with normal rats, plasma aldosterone levels were increased by 397% in SU-5416/hypoxia-induced PAH (352. nϭ3-4 rats per condition, Pϭ0.18) and PASP (80.5Ϯ4.9 versus 61.5Ϯ6.5 mm Hg, Pϭ0.048, nϭ5) ( Figure 4B ) without significantly influencing body weight, heart rate, mean arterial pressure, cardiac index, left ventricular end-diastolic pressure, or systemic vascular resistance. Collectively, our findings demonstrate that hyperaldosteronism modulates PAH and that a class effect exists among mineralocorticoid receptor antagonists for abrogating the adverse consequences of aldosterone on pulmonary vascular remodeling, pulmonary vascular resistance, and PASP in 2 animal models of PAH in vivo.
ET-1 Increases Aldosterone Levels in Pulmonary Artery Endothelial Cells
Because ET-1 levels associated positively with lung CYP11B2 protein expression and aldosterone levels in MCTinduced PAH in vivo, we explored the possibility that ET-1 is an unrecognized stimulus of extra-adrenal aldosterone synthesis in HPAECs in vitro. We first confirmed that, in comparison with V-treated cells, ET-1 (1, 10, 100 nmol/L) increased CYP11B2 protein expression levels (157.3Ϯ27.5 versus 180.4Ϯ13.4 versus 234.8Ϯ4.3% control, respectively, PϽ0.02, nϭ3) (online-only Data Supplement Figure VIA) , which correlated with a concentration-dependent increase in aldosterone levels detected in the cell culture medium (241.1Ϯ44.8 versus 283.5Ϯ94.7 versus 396.0Ϯ116.5% control, respectively, PϽ0.04, nϭ4) (online-only Data Supplement Figure VIB) . Consistent with previous reports in dispersed adrenal cortical cells, 6, 14 ET-1 increased aldosterone levels via activation of the ET B receptor in HPAECs (onlineonly Data Supplement Figure VII) .
We next sought to determine the mechanism by which ET-1 increases aldosterone levels in HPAECs. In adrenal cortical Y-1 cells, the transcription factor peroxisome proliferator-activated receptor gamma coactivator-1␣ (PGC-1␣) interacts with the nuclear receptor protein steroidogenesis factor-1 (SF) to regulate CYP11B2 gene transcription and induce aldosterone synthesis. 15 Therefore, to determine whether ET-1 increased aldosterone synthase protein levels by this mechanism in HPAECs, we first explored the effect of ET-1 on PGC-1␣ and SF protein expression levels in these cells. In comparison with V-treated cells, exposure to ET-1 (1, 10, 100 nmol/L) for 24 hours induced a concentrationdependent increase in PGC-1␣ protein expression levels (176. 5Ϯ52.8 versus 224.7Ϯ68.1 versus 296.7Ϯ145.8% control, respectively, PϽ0.02, nϭ3) ( Figure 5A ). ET-1 had no effect on SF protein levels; however, ET-1 did increase the association between PGC-1␣ and SF as demonstrated by coimmunoprecipitation (1260Ϯ104 versus 160Ϯ71 arbitrary units, PϽ0.001, nϭ3) ( Figure 5B) .
We next performed a chromatin immunoprecipitation assay to assess the effect of ET-1 (10 nmol/L) for 24 hours on PGC-1␣ and/or SF association with the CYP11B2 promoter. PGC-1␣ alone did not bind to the CYP11B2 promoter in cells treated with either V or ET-1; however, in comparison with V, ET-1 induced a significant increase in SF binding to the CYP11B2 promoter (16.3Ϯ9.8 versus 61.6Ϯ9.3 arbitrary units, PϽ0.03, nϭ3) ( Figure 5C ). Collectively, these data indicate that ET-1 stimulates PGC-1␣ binding with SF, which, in turn, promotes the association of SF to the promoter region of CYP11B2 to upregulate CYP11B2 protein expression levels. We confirmed that PGC-1␣ stimulation is linked functionally to aldosterone synthesis in cells treated with the selective PGC-1␣ agonist pioglitazone (50 mol/L) for 24 hours, which, in comparison with V, increased aldosterone levels by 365% (PϽ0.001, nϭ3) ( Figure 5D ). Thus, ET-1 increases extra-adrenal aldosterone synthesis in endothelial cells via upregulation of CYP11B2 in a PGC1-␣/SF-dependent manner. 
Aldosterone Increases Oxidant Stress in HPAECs
Next, to determine whether hyperaldosteronism in PAH could contribute to pulmonary vascular dysfunction akin to what we observed previously in the systemic vasculature, 4,7 we investigated the effect of aldosterone on ROS levels in HPAECs. Cells were exposed to increasing concentrations of aldosterone (10 Ϫ9 , 10 Ϫ8 , 10 Ϫ7 mol/L) for 12 to 36 hours and H 2 O 2 levels were measured by Amplex Red assay. In comparison with V-treated cells, maximal H 2 O 2 accumulation was observed in cells treated with aldosterone (10 Ϫ7 mol/L) for 24 hours (65.4Ϯ1.6 versus 100.6Ϯ3.5 mol/L/mg protein, PϽ0.001, nϭ3); this effect was abrogated by 56% in aldosterone-treated cells coincubated with spironolactone (PϽ0.01, nϭ3), indicating that a majority of aldosteroneinduced H 2 O 2 formation was due to mineralocorticoid receptor activation (online-only Data Supplement Figure VIIIA ). Because no further H 2 O 2 generation was observed in aldosterone-treated cells beyond 24 hours, subsequent experiments were performed at this time point using (patho)physiologically relevant levels of aldosterone similar to those observed in MCT-or SU-5416/hypoxia-treated rats with PAH in vivo. Furthermore, the observed increase in ROS was due to aldosterone, and not ET-1, because ET-1 (10 nmol/L) had no effect on H 2 O 2 levels in comparison with V-treated cells (Pϭ0.43, nϭ4). NADPH oxidase type 4 (NOX4) is implicated as a key source of vascular ROS generation in pulmonary hypertension and human vascular endothelial cells exposed to pathophysiologic concentrations of aldosterone. 16, 17 The primary product of NOX4 activation is H 2 O 2 , and its formation is closely aligned to changes in NOX4 protein expression. 17 Therefore, we examined the effect of aldosterone on NOX4 expression in HPAECs as a potential mechanism by which to explain the aldosterone-mediated increase in H 2 O 2 formation. In comparison with V-treated cells, aldosterone (10 Ϫ9 , 10 Ϫ8 , 10 Ϫ7 mol/L) increased protein levels of NOX4 (134.6Ϯ16.5 versus 146.3Ϯ12.4 Ϯ versus 157.0Ϯ4.4% control, respectively, PϽ0.02, nϭ3) and of p22 phox (1009.4Ϯ167.0 versus 961Ϯ226.2 versus 829.5Ϯ295.6% control, respectively, PϽ0.01, nϭ3), a NOX4 subunit that is required for NOX4mediated H 2 O 2 formation, in a concentration-dependent manner (online-only Data Supplement Figure VIIIB and VIIIC).
Aldosterone Decreases ET B -Dependent Activation of eNOS and NO · Levels
We next investigated the effect of ET B receptor activation by ET-1 (10 nmol/L) on levels of the NO · metabolite nitrite (NO 2 Ϫ ). In comparison with V-treated cells, ET-1 increased NO 2
Ϫ generation with a maximum effect observed at 10 minutes (29.4Ϯ3.6 versus 139.4Ϯ31.8 mol/L/g protein, PϽ0.001, nϭ3). We then evaluated the effect of aldosterone on ET B -stimulated NO · levels. Without influencing protein expression of ET B , or inducing expression of ET A (which is not constitutively expressed in HPAECs) 18 (online-only Data Supplement Figure IX) , exposure to aldosterone (10 Ϫ7 mol/L) for 24 hours decreased ET B -mediated NO 2 Ϫ levels by 60.3% (PϽ0.01, nϭ3). Coincubation with spironolactone (10 mol/L) restored NO 2 Ϫ levels to those observed in cells stimulated with ET-1 in the absence of aldosterone ( Figure 6A ). We and others have demonstrated previously that, in the absence of oxidant stress, NO · metabolism to NO 2 Ϫ and nitrate (NO 3 Ϫ ) occurs in a ratio that favors NO 2 Ϫ by approximately 2:1, but that this ratio shifts in favor of increased NO 3 Ϫ formation in the presence of the superoxide anion, owing to the interaction of NO 2 Ϫ with the superoxide anion to generate peroxynitrate (O 2 NOO Ϫ ) 7 or via tautomerization of peroxynitrite (ONOO Ϫ ) to NO 3 Ϫ . 19 In HPAECs, ET-1 alone did not affect the NO 2 Ϫ /NO 3 Ϫ ratio significantly compared with V. In contrast, exposure to aldosterone decreased the NO 2 Ϫ /NO 3 Ϫ ratio by 62% in ET-1-stimulated cells, which was restored fully by coincubation of aldosterone with spironolactone (PϽ0.04, nϭ3) (online-only Data Supplement Figure XA ). This effect was likely mediated by increased ONOO Ϫ formation as aldosterone-treated HPAECs had increased levels of 3-nitrotyrosine, a marker of ONOO Ϫ , in comparison with cells stimulated with V or ET-1 alone (24.1Ϯ3.3 versus 31.2Ϯ3.2 versus 46.8Ϯ6.6 arbitrary units, PϽ0.02, nϭ5) (online-only Data Supplement Figure XB) .
We also examined the effect of aldosterone on ET-1stimulated eNOS activity. Without influencing eNOS protein levels, aldosterone decreased eNOS activity in ET-1 (10 nmol/L)-stimulated cells (18.5Ϯ3.5 versus 7.6Ϯ2.4 [ 14 C]Lcitrulline cpm/mg protein, nϭ3, PϽ0.02) ( Figure 6B ), leading to a decrease in total NO · metabolite (NOx: NO 2 Ϫ ϩ NO 3 Ϫ ) formation (157.9Ϯ12.7 versus 103.4Ϯ12.2 mol/L per g protein, PϽ0.01, nϭ3). Coincubation with spironolactone increased NO · metabolite levels in aldosterone-treated cells stimulated with ET-1 by 87% (PϽ0.02, nϭ3) ( Figure  6C ). Taken together, these data demonstrate that aldosterone diminished levels of bioavailable NO · in ET-1-stimulated cells by decreasing ET-1-mediated eNOS activity to limit NO · generation, increasing ONOO Ϫ formation, and by oxidizing NO 2 Ϫ to NO 3 Ϫ .
Aldosterone Decreases ET B -dependent NO · Levels by Oxidative Modification of Cys405
Given that aldosterone decreased ET-1-stimulated eNOS activity and NO · generation, we postulated that aldosterone affected ET B receptor function. Because aldosterone induced H 2 O 2 formation and ET B contains functionally essential cysteinyl thiol residues in its eNOS-activating region, it is plausible that aldosterone may induce an oxidative posttranslational modification of ET B that influences receptor func- Figure 6 . Aldosterone decreases ET B -dependent synthesis of nitric oxide (NO · ). A, HPAECs were exposed to vehicle (V) or aldosterone (ALDO) (10 Ϫ7 mol/L) for 24 hours in the presence or absence of spironolactone (SP) (10 mol/L) and NO 2 Ϫ formation was assessed. Before analysis, cells were exposed to ET-1 (10 nmol/L) for 10 minutes to stimulate ET B signaling (nϭ4). B, The effect of aldosterone (ALDO) on ET B -dependent activation of endothelial nitric oxide synthase (eNOS) was determined (nϭ4). C, The effect of ALDO on ET Bdependent NO · generation was assessed by measuring total NO · metabolite levels (NOx: NO 2 Ϫ ϩ NO 3 Ϫ ) (nϭ3). D, HPAECs were exposed to V, hydrogen peroxide (H 2 tion. To examine ET B for oxidation of cysteinyl thiols, protein extracts from HPAECs were treated with V, aldosterone (10 Ϫ7 mol/L) for 24 hours, or H 2 O 2 (200 mol/L) for 20 minutes, and free thiols were blocked with iodoacetamide and N-ethylmaleimide. Disulfides were reduced with tris(2carboxyethyl)phosphine hydrochloride, and previously oxidized (now reduced) cysteines were labeled with polyethylene glycol-conjugated maleimide (molecular mass 10 kDa). In this way, each reduced disulfide bond yields a shift in the apparent molecular mass of the reduced protein by 20 kDa. Western analysis using an antibody specific to the region of ET B containing Cys405 revealed that only the reduced form of ET B was present (50 kDa) in V-treated cells; however, bands at 70 kDa and 90 kDa were evident in cells treated with H 2 O 2 or aldosterone, indicating the de novo formation of 1 or 2 disulfide bonds under these conditions of increased oxidant stress ( Figure 6D ).
To support these findings, we determined whether aldosterone modulates the formation of other higher oxidative intermediates of ET B Cys405. Cells were treated with V or aldosterone (10 Ϫ7 mol/L) for 24 hours, and the region of ET B containing Cys405 was immunoprecipitated by using the specific ET B containing Cys405 antibody (Santa Cruz). Western analysis using an antisulfenic acid (R-SOH) antibody (derivatized with dimedone) 20 (Millipore) revealed that, in comparison with V-treated cells, aldosterone increased ET B -SOH protein expression levels by 639% (Pϭ0.04, nϭ3) ( Figure 6E ).
To confirm that oxidative modification of Cys405 has functional implications for ET B -dependent NO · generation, we transiently transfected COS-7 cells with human DNAs coding for wild-type (WT) eNOS and WT-ET B or a mutant ET B containing a substitution of cysteine with alanine, which is insensitive to oxidant stress, at position 405 (C405A-ET B ). Expression of transiently transfected WT-eNOS and WT-ET B or C405A-ET B DNA was established by immunoblotting ( Figure 7A ). Additionally, immunoblotting of polyethylene glycol-conjugated maleimide-labeled extracts confirmed that, in comparison with WT-ET B , in which H 2 O 2 (200 mol/L for 20 minutes) induced the formation of 1 or 2 disulfide bonds, C405A-ET B was resistant to the formation of disulfide bonds ( Figure 7B ). Next, COS-7 cells expressing eNOS and WT-ET B or C405A-ET B were exposed to H 2 O 2 (200 mol/L) for 60 minutes, and ET B -dependent NO · synthesis was assessed. This treatment time point was selected because activation of eNOS by H 2 O 2 is time dependent and attenuated fully within 60 minutes following exposure of eNOS to H 2 O 2 . 21 After this time, the medium was replaced and cells were treated with ET-1 (10 nmol/L) for 10 minutes to stimulate ET B signal transduction. Although exposure to H 2 O 2 decreased ET-1-stimulated NO 2 Ϫ formation by 78.0% in WT-ET B -transfected cells in comparison with V-treated cells (PϽ0.005, nϭ4), this effect was attenuated significantly in C405A-ET B -transfected cells in which H 2 O 2 decreased nitrite levels by only 45.0% in comparison with V-treated cells (Pϭ0.07, nϭ4) ( Figure 7C ). Taken together, these data confirm that Cys405 is a redox-sensitive, functional cysteinyl thiol whose oxidation to sulfenic acid impairs ET B -dependent NO · generation.
Discussion
In this study, we found that elevated levels of ET-1 in PAH are associated with increased plasma and lung tissue levels of aldosterone, indicating that the pathophysiological effects attributed to ET-1 may occur, in part, as a result of systemic and local hyperaldosteronism. This conclusion was confirmed in vivo by demonstrating that the mineralocorticoid receptor antagonists spironolactone or eplerenone, given in the absence of ET-1 blockade, decreased PASP, RV hypertrophy, pulmonary vascular resistance, and pulmonary vascular remodeling. These effects did not occur as a result of changes in left-sided hemodynamics or differences in plasma ET-1 levels as a result of mineralocorticoid receptor blockade. We demonstrated that ET-1 increases aldosterone levels through a mechanism that involves upregulation of CYP11B2, the rate-limiting enzyme in aldosterone synthesis, in a PGC-1␣/ SF-dependent manner. The functional consequences of elevated aldosterone levels include increased oxidant stress and decreased bioavailable NO · . Although diminished NO · levels resulted, in part, from its consumption by ROS, as demonstrated by an increase in ONOO Ϫ formation, we also found a novel mechanism to explain the aldosterone-mediated decrease in ET-1-stimulated NO · formation: oxidation of cysteinyl thiols (Cys405) in the eNOS-activating region of the ET B receptor (to sulfenic acid and the disulfide form) ( Figure  8 ). Thus, aldosterone contributes to high pulmonary vascular tone by oxidizing cysteinyl thiols in ET B , which, in turn, acts as a redox switch to impair ET-1-stimulated endothelial NO · generation.
Other studies have linked hyperaldosteronism to end-stage disease in idiopathic pulmonary hypertension. 22 Although studies to date examining the role of mineralocorticoid receptor antagonism in PAH are limited to case reports, 23 a clinical trial was recently announced to examine the hypothesis that secondary hyperaldosteronism modulates the adverse effects of PAH leading to RV failure. In this study, patients will be treated with spironolactone, and the effect of mineralocorticoid receptor blockade on pulmonary hemodynamics and World Health Organization functional class will be examined. 24 Although this study focuses on the efficacy of aldosterone antagonism once PAH is established, our data suggest that aldosterone antagonism may also have benefit when started early in the disease course.
We implicate ET-1 as the stimulus for increased lung tissue and plasma aldosterone levels in PAH. Using the MCT rat model of PAH, we confirmed a 3-fold increase in plasma ET-1 levels, which supports previous studies that reported an increase in ET-1 levels and showed that ET-1 contributed to the pathogenesis of PAH. 12 The levels of ET-1 that we observed were 1000-fold higher than the level required to stimulate aldosterone secretion from adrenocortical cells in vitro. 6 Furthermore, the levels of plasma ET-1 measured in this study, akin to those observed in patients with PAH, 25 were sufficient to increase plasma aldosterone levels by 442%. These plasma aldosterone levels are similar to what have been observed in patients with left-sided congestive heart failure and secondary pulmonary hypertension. 26, 27 Moreover, our study likely underestimated the maximal level of hyperaldosteronism achieved in PAH, because we measured plasma levels antecedent to advanced stage disease, which is associated with decreased cardiac output vis-à-vis cor pulmonale that results in a decline in PASP and compensatory (over)activation of the renin-angiotensin-aldosterone system. 27 The mechanism by which ET-1 stimulates aldosterone secretion in HPAECs involved upregulation of the expression of CYP11B2, the rate-limiting enzyme in aldosterone biosynthesis. The concept of extra-adrenal aldosterone synthesis by the vascular endothelium remains controversial. CYP11B2 expression in human pulmonary vascular endothelial and smooth muscle cells has been demonstrated and shown to be responsive to angiotensin II or potassium, resulting in an increase in local aldosterone production. 28 In contrast, other studies performed in HPAECs failed to show an effect of angiotensin II on CYP11B2 transcription or aldosterone production 29 ; however, these studies were performed on cells at passage 14 or older, which may adversely affect global vascular endothelial mRNA and protein expression levels. Moreover, this earlier study measured aldosterone production with the use of an assay with a lower limit of detection reported to be 20 pg/mL. Our study used a more sensitive assay with a lower limit of detection of 7 pg/mL. Our observation that CYP11B2 expression was increased via upregulation of PGC-1␣ and its association with SF at the promoter region of the CYP11B2 gene confirms previous work in adrenal cortex-derived Y1 cells that demonstrated a similar mechanism of CYP11B2 upregulation. 15 We were also able to provide additional evidence for this mechanism by PGC-1␣ agonism with the thiazolidinedione, pioglitazone. Notwithstanding this finding, the relationship between thioglitazone/PGC-1␣ and aldosterone remains unresolved.
In one study performed in healthy volunteers, pioglitazone treatment for 6 weeks increased circulating aldosterone levels, 30 whereas rosiglitazone has been linked to aldosteroneindependent plasma volume expansion through inhibition of sodium transport in the renal collecting duct. 31 More recently, studies performed in adrenocortical H295R cells demonstrated that pioglitazone suppressed CYP11B2 expression in angiotensin II-stimulated cells, and this effect was associated with a modest decrease in aldosterone secretion. 32 Although we now report differing results, we believe they may be attributable to the cell types studied, and the duration of exposure to pioglitazone and angiotensin II, as well. We and others have shown previously that the adverse effects of aldosterone on the systemic vasculature include increased oxidant stress and decreased bioavailable NO · that promotes endothelial dysfunction and impairs vascular reactivity. 4, 7, 26, 33 Our finding of increased pulmonary endothelial oxidant stress is not surprising, because others have reported an increase in ROS production owing to increased NOX1 expression in the small muscularized arteries isolated from the MCT rat model of PAH. 34 Here, we focused selectively on oxidant stress in the endothelium and found an increase in expression of NOX4 and the NOX4 subunit p22 phox , indicating that both NOX1 and NOX4 systems may be operative in PAH. Furthermore, our in vitro studies attribute this increase in NADPH oxidase activity to aldosterone and not to ET-1. Conversely, other studies have reported that ET-1 decreased H 2 O 2 production in fetal pulmonary artery endothelial cells in an ET B -dependent manner 35 ; however, these studies were not performed in a time frame that would afford upregulation of aldosterone synthesis by ET-1.
Although there is a consensus opinion that PAH is associated with a decrease in eNOS activity and bioavailable NO · , several mechanisms have been demonstrated to explain this phenomenon. In the setting of increased oxidant stress, NO · reacts with superoxide to form ONOO Ϫ , which we observed in our study. Other mechanisms include the uncoupling of eNOS to form superoxide in preference to NO · , upregulation of arginase II, 36 oxidation of tetrahydrobiopterin, 37 altered S-nitrosoglutathione reductase activity, 38 and caveolin-1 deficiency. 39 We now identify an additional mechanism to explain the decrease in eNOS activity and bioavailable NO · : dysfunctional ET-1/ET B -eNOS signaling in the setting of elevated aldosterone levels owing to oxidative posttranslational modification of redox-sensitive cysteinyl thiol(s) in the ET B receptor. Oxidation of cysteine residues to form higher oxidative intermediates of cysteine, including sulfenic acid and the disulfide form, is known to occur under conditions of oxidant stress and to regulate protein function. 40 The ET B receptor is a 7 transmembrane domain G-coupled protein receptor with a carboxyterminal cytoplasmic tail that contains 3 functional cysteine residues: Cys402, Cys403, and Cys405. 9 Here, we report that these cysteines are oxidatively modified, which is associated with functional consequences for ET Bdependent eNOS activity. It is known that these cysteines are subject to posttranslational modification, such as palmitoylation, and site-directed mutagenesis has revealed that palmitoylation is required for coupling with G i but not G q subunits. 41 In the current work, the relationship between ET B cytoplasmic tail cysteines, palmitoylation, and eNOS was not explored. Interestingly, an in vitro study using a synthetic peptide of ET B constructed to contain residues 390 to 409, and, therefore, including the 3 cytoplasmic tail cysteines, was shown to bind eNOS and inhibit its activity with an EC 50 of 3Ϯ1.8 mol/L. 42 Although that study did not examine the cysteinyl residues directly for posttranslational modification(s), our observation that oxidative posttranslational modification of ET B Cys405 is associated with impaired ET Bdependent NO · generation suggests that this cysteine functions as a redox switch to modulate eNOS activity. In support of this concept is our observation that site-directed mutagenesis of Cys405 rendered ET B resistant to oxidant stress-induced sulfenic acid and disulfide formation, and, as a result, improved redox-sensitive signaling. It is, however, important to acknowledge that our methods did not use liquid chromatography-mass spectrometry, which is required to definitively characterize this effect. Moreover, our observation that site-directed mutagenesis of Cys405 alone restored ET B -dependent NO · generation incompletely in the presence of pathological concentrations of H 2 O 2 suggests further that Cys402 and Cys403 may also be redox-sensitive cysteinyl thiols involved in ET B -eNOS signal transduction. Our finding that cysteines in the ET B cytoplasmic tail are oxidatively modified is also supported by the observation that global sulfhydryl levels are decreased in lung tissue isolated from rats with MCT-induced PAH in comparison with controls. 43 Our results may account, in part, for limitations in the clinical efficacy of endothelin receptor antagonism for patients with PAH, namely, currently available ET receptor antagonists are believed to improve pulmonary vascular tone primarily by attenuating ET A -mediated pulmonary vasoconstriction in pulmonary vascular smooth muscle cells, and, therefore, these drugs do not address the potential contribution of abnormal ET B signal transduction in HPAECs to pulmonary vascular dysfunction in PAH. Along these lines, our findings suggest that by preventing aldosterone-induced oxidation of ET B , mineralocorticoid receptor antagonism preserves normal ET-1-ET B vasodilatory signaling to maintain levels of NO · in HPAECs and attenuate pulmonary vascular remodeling in PAH in vivo (Figure 8 ). Importantly, however, the effect of spironolactone/eplerenone on the development of plexiform lesions was not specifically ad-dressed in this study. Thus, the role of mineralocorticoid receptor antagonists in modulating cardiopulmonary hemodynamic improvements in forms of PAH that are characterized primarily by the plexiform arteriopathy remains unknown.
In summary, we identify aldosterone as an unrecognized biological intermediate that modulates the adverse vascular effects of ET-1 in PAH. We describe a novel mechanism by which to explain the defect in ET-1/ET B -eNOS signaling associated with PAH: oxidative posttranslational modification of the ET B receptor. Our observations demonstrate further that a class effect exists for mineralocorticoid receptor antagonists and that these agents ameliorate the PAH phenotype by improving pulmonary hemodynamics and (mal)adaptive pulmonary vascular remodeling. Collectively, these findings suggest that mineralocorticoid receptor antagonism in PAH may represent a novel pharmacotherapeutic strategy to improve pulmonary vascular dysfunction and its attendant sequelae in patients with PAH.
